Management of chronic myeloid leukemia: Targets for molecular therapy

被引：12

作者：

Barnes, DJ ^{[1
]}

Melo, JV ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, Fac Med, London W12 0NN, England

来源：

SEMINARS IN HEMATOLOGY | 2003年 / 40卷 / 01期

关键词：

D O I：

10.1053/shem.2003.50002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：34 / 49

页数：16

共 91 条

[1]

Adjei AA, 2000, CANCER RES, V60, P1871

[2]

AKIYAMA T, 1987, J BIOL CHEM, V262, P5592

[3]

AMROLIA PJ, IN PRESS BLOOD

[4]

An WG, 2000, CELL GROWTH DIFFER, V11, P355

[5]

ANAFI M, 1993, BLOOD, V82, P3524

[6] Disabling receptor ensembles with rationally designed interface peptidomimetics [J].

Berezov, A ;

Chen, JQ ;

Liu, QD ;

Zhang, HT ;

Greene, MI ;

Murali, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (31) :28330-28339

[7] STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon' [J].

Blagosklonny, MV .

LEUKEMIA, 2002, 16 (04) :570-572

[8] Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs [J].

Blagosklonny, MV .

LEUKEMIA, 2002, 16 (04) :455-462

[9] Novel antisense and peptide nucleic acid strategies for controlling gene expression [J].

Braasch, DA ;

Corey, DR .

BIOCHEMISTRY, 2002, 41 (14) :4503-4510

[10] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

← 1 2 3 4 5 6 7 8 9 10 →